ZDA
RMD icon

Zweig-DiMenna Associates’s ResMed RMD Stock Holding History

Zweig-DiMenna Associates’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-4,700
Closed -$221K – 286
2013
Q4 		$221K Buy
+4,700
New +$238K 0.01% 245

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Zweig-DiMenna Associates's RMD Position: Q1 2014 in Review

Zweig-DiMenna Associates sold out of ResMed (RMD) in Q1 2014, closing a stake of 4,700 shares — an estimated $221K sold.

Zweig-DiMenna Associates first reported a position in RMD in Q4 2013 and held it in 1 quarter. The position peaked at $221K in Q4 2013. 318 funds tracked by Wall St. Rank hold RMD as of Q1 2014.

  • Zweig-DiMenna Associates reported no remaining ResMed position as of Q1 2014 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 4,700 ResMed shares in Q1 2014, an estimated $221K.
  • Zweig-DiMenna Associates first reported a position in ResMed in Q4 2013 and held it in 1 quarter.
  • Zweig-DiMenna Associates's ResMed position peaked at $221K in Q4 2013.
  • 318 funds tracked by Wall St. Rank held ResMed as of Q1 2014.

Based on Zweig-DiMenna Associates's 13F filing for Q1 2014, filed 8 May 2014.